its subsidiary Biocon Biologics has completed the integration of the biosimilars business acquired from US-based pharma company Viatris in over 70 countries, according to a Wednesday filing.
Biocon Biologics had agreed to acquire Viatris Inc's biosimilars business for $3.33 billion in February 2022.
"The transitioning will allow Biocon Biologics to meaningfully expand the geographic reach of the existing biosimilars portfolio and future pipeline into growth markets where Viatris has existing sales infrastructure and local market expertise," Susheel Umesh, chief commercial officer - emerging markets at Biocon Biologics.
Biocon Biologics had agreed to acquire Viatris Inc's biosimilars business for $3.33 billion in February 2022.
"The transitioning will allow Biocon Biologics to meaningfully expand the geographic reach of the existing biosimilars portfolio and future pipeline into growth markets where Viatris has existing sales infrastructure and local market expertise," Susheel Umesh, chief commercial officer - emerging markets at Biocon Biologics.